Journal of Volgograd State Medical UniversityJournal of Volgograd State Medical University1994-94801994-9499Volgograd State Medical University11928410.19163/1994-9480-2018-3(67)-72-75Research ArticleCYTOKINE PROFILE IN PATIENTS WITH GOUTY ARTHRITIS IN COMBINATION WITH METABOLIC SYNDROMEZhigulinaK. Vkristya_87@inbox.ruShilovaL. N-AlexandrovA. V.-SabanovA. V.-FSBEI HE «Volgograd State Medical University» of Public Health Ministry of the Russian FederationFSBSI «Scientific Research Institute of Clinical and Experimental Rheumatology named after А. B. Zborowski»15032018153727518122022Copyright © 2018, Zhigulina K.V., Shilova L.N., Alexandrov A.V., Sabanov A.V.2018There were 60 patients with reliable PA under observation (the diagnosis was established according to the classification criteria ACR / EULAR, 2015). All patients were divided into two groups: Group 1 - 40 patients with gout without MS signs, the second group included PA patients with signs of MS (75 % for women, 25 % for men). The average duration of the disease was (8,2 ± 3,5) years. In 25 patients there was a family history. Despite the differences in etiology and pathogenesis, the variety of clinical manifestations of rheumatic diseases (RH), the basis of most of them is chronic inflammation. A significant role in the formation of inflammation, which has a number of common immune mechanisms in some of the most common RH (rheumatoid arthritis, psoriatic arthritis, gout), belongs to cytokines, including tumor necrosis factor-а (TNF-а). It is with the hyperproduction of cytokines associated with an increased risk of atherosclerosis and associated with it vascular complications. Of particular importance is the metabolic syndrome, which is often observed in patients with gout. On the one hand, the metabolic syndrome is reversible, and on the other - significantly increases the risk of such socially significant diseases as type 2 diabetes and atherosclerosis.gout arthritismetabolic syndromeinterleukin-6interleukin-10подагрический артритметаболический синдромфактор некроза опухолей-аинтерлейкин-6интерлейкин-10tumor necrosis-а[Насонов Е.Л. Фактор некроза опухоли-а - новая мишень для противовоспалительной терапии ревматоидного артрита // Русс. мед. жур. - 2000. - № 17. - С. 718-22.][Насонов Е.Л., Насонова В.А., Барскова В.Г. Механизмы развития подагрического воспаления // Терапевтический архив. - 2006. - № 6. - С. 77-84.][Насонова В.А., Барскова В.Г. Подагра в конце 20 века // Consilium Medicum. - 2002. - № 8. - С. 400-402.][Паньшина Н.Н., Шилова Л.Н. Особенности цитокинового профиля у больных псориатическим артритом // Медицинский вестник Северного Кавказа. - 2017. -Т. 12, № 4. - С. 355-357.][Bjorntorp P. Visceral fat accumulation: the missing link between psychosocial factors and cardiovascular disease? // J. Intern. Med. - 1991. - Vol. 230. - P. 195-201.][Feldman M., Brenan F.M., Maini R.N. Role of cytokines in rheumatoid arthritis // Ann. Rev. Immunol. - 1996. -№ 14. - С. 397-440.][Khan M.A. Update on psoriasis as it relates to spondyloarthropathies. EULAR, 2001. Ann. Rheum. Dis. 2001, 60, suppl. 1, SP0033.][Sjostrom C.D., Hakangard A.C., Lissner L. et all. Body compartment and subcutaneous adipose tissue distribution - risk factor patterns in obese subjects // Obesity Res. - 1995. - Vol. 3. - P. 9-22.][Schumacher H.R.Jr. Crystal-induced arthritis: an overview // Am. J. Med. - 1996. - Vol. 100. - P. 46-52.]